These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16472937)

  • 1. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.
    Fujita T; Teh BS; Timme TL; Mai WY; Satoh T; Kusaka N; Naruishi K; Fattah EA; Aguilar-Cordova E; Butler EB; Thompson TC
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):84-90. PubMed ID: 16472937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
    Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
    Shalev M; Kadmon D; Teh BS; Butler EB; Aguilar-Cordova E; Thompson TC; Herman JR; Adler HL; Scardino PT; Miles BJ
    J Urol; 2000 Jun; 163(6):1747-50. PubMed ID: 10799174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
    van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
    Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.
    Ayala G; Satoh T; Li R; Shalev M; Gdor Y; Aguilar-Cordova E; Frolov A; Wheeler TM; Miles BJ; Rauen K; Teh BS; Butler EB; Thompson TC; Kadmon D
    Mol Ther; 2006 Apr; 13(4):716-28. PubMed ID: 16480930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up after triple treatment of prostate cancer stage pT3.
    Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
    Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.
    Miles BJ; Shalev M; Aguilar-Cordova E; Timme TL; Lee HM; Yang G; Adler HL; Kernen K; Pramudji CK; Satoh T; Gdor Y; Ren C; Ayala G; Wheeler TM; Butler EB; Kadmon D; Thompson TC
    Hum Gene Ther; 2001 Nov; 12(16):1955-67. PubMed ID: 11686937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard treatments induce antigen-specific immune responses in prostate cancer.
    Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH
    Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV; Renshaw AA; Loffredo B; Chen MH
    Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
    Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
    Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
    Hinata N; Shirakawa T; Terao S; Goda K; Tanaka K; Yamada Y; Hara I; Kamidono S; Fujisawa M; Gotoh A
    Int J Urol; 2006 Jun; 13(6):834-7. PubMed ID: 16834676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer.
    Yassa M; Fortin B; Fortin MA; Lambert C; Van Nguyen T; Bahary JP
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):58-63. PubMed ID: 18406883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.